Article Text
PDF
Abstract
Introduction/Background Endometrial cancer is the most frequently treated gynaecological cancer. The current standard of care of endometrial cancer involves resection, often followed by adjuvant treatment with radiotherapy or chemotherapy. However, some patients may not be candidates for surgery and require alternative treatment options, such as radiotherapy. External beam radiotherapy (EBRT), brachytherapy (BT) or both in combination can be used in this scenario. Recent advances in EBRT and the advent of high dose rate (HDR) brachytherapy have improved tumour delineation and dose delivery. We report survival data of patients with inoperable endometrial cancer treated with definitive EBRT ± BT.
Methodology We conducted a retrospective review of patients with inoperable endometrial cancer who underwent definitive radiotherapy (BT ± EBRT) between 2017 and 2023 at our single center. Patient and disease characteristics, including stage, grade, and histopathological subtype, were collected, and survival data were obtained through electronic medical records.
Results Seven patients with inoperable endometrial cancer were included in the analysis. Six patients had stage III disease, with IIIB (57.14%) and IIIC (28.58%) sub-stages, and one had stage IA disease (14.28%). The median age of the patients was 70 (range 42–83 years). Five had endometrioid adenocarcinoma, two had carcinosarcoma. All had EBRT with lowest total dose of 45Gy (receiving a simultaneous integrated boost to positive nodes if present). Six patients had sequential brachytherapy (21–28Gy) and three of them received concurrent chemotherapy. Only one patient had evidence of progression of endometrial disease, 10 months after finishing treatment, and died five months later. One patient was lost to follow-up. Censored overall survival data is described, with a range from 8–42 months.
Conclusion Definitive radiotherapy treatment can be used effectively and safely in those medically inoperable or with inoperable endometrial cancer, including those with Stage III disease.
Disclosures None.